We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
(-13%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
147.28%
Top 10 Holdings %
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Constellation Brands
STZ
$22.7B
| $392K | 0.52% |
2,418
-17,582
| -88% | -$2.74M |
|
52
CALL
Apple
AAPL
$4.9T
| $385K | 0.51% |
+104,000
| New | +$3.42M |
|
53
Ligand Pharmaceuticals
LGND
$6.08B
| $379K | 0.5% |
+5,740
| New | +$378K |
|
54
uniQure
QURE
$2.77B
| $376K | 0.5% |
65,058
-100
| -0.2% | -$602 |
|
55
PUT
Vertex Pharmaceuticals
VRTX
$123B
| $366K | 0.48% |
49,900
+19,000
| +61% | +$1.67M |
|
|
PTLA
56
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $365K | 0.48% |
+9,305
| New | +$296K |
|
|
K
57
PUT
DELISTED
Kellanova
K
| $353K | 0.46% |
118,535
+97,235
| +457% | +$6.71M |
|
|
58
CALL
Vertex Pharmaceuticals
VRTX
$123B
| $353K | 0.46% |
17,000
+7,500
| +79% | +$660K |
|
59
CALL
Abbott
ABT
$175B
| $313K | 0.41% |
26,500
+4,000
| +18% | +$173K |
|
60
Ulta Beauty
ULTA
$20.6B
| $285K | 0.38% |
+1,000
| New | +$274K |
|
|
CELG
61
CALL
DELISTED
Celgene Corp
CELG
| $285K | 0.38% |
+43,500
| New | +$5.21M |
|
|
PNRA
62
CALL
DELISTED
Panera Bread Co
PNRA
| $280K | 0.37% |
21,200
+4,000
| +23% | +$908K |
|
63
Cognizant
CTSH
$21.2B
| $274K | 0.36% |
+4,600
| New | +$264K |
|
|
MON
64
CALL
DELISTED
Monsanto Co
MON
| $272K | 0.36% |
46,700
-7,800
| -14% | -$863K |
|
65
Hain Celestial
HAIN
$50.6M
| $262K | 0.34% |
+7,034
| New | +$265K |
|
|
B
66
Barrick Mining
B
$58.5B
| $257K | 0.34% |
+13,510
| New | +$249K |
|
67
Alphabet (Google) Class A
GOOGL
$4.23T
| $254K | 0.33% |
+6,000
| New | +$252K |
|
68
Alnylam Pharmaceuticals
ALNY
$35.7B
| $247K | 0.33% |
4,826
-1,700
| -26% | -$78.6K |
|
|
CLVS
69
DELISTED
Clovis Oncology, Inc.
CLVS
| $243K | 0.32% |
+3,821
| New | +$232K |
|
|
NBRV
70
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $238K | 0.31% |
79
-253
| -76% | -$615K |
|
71
CALL
Bristol-Myers Squibb
BMY
$124B
| $230K | 0.3% |
+34,600
| New | +$1.9M |
|
72
Pacira BioSciences
PCRX
$1.01B
| $228K | 0.3% |
+5,000
| New | +$216K |
|
73
Puma Biotechnology
PBYI
$434M
| $225K | 0.3% |
+6,039
| New | +$220K |
|
|
LUMO
74
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $218K | 0.29% |
3,278
-2,333
| -42% | -$333K |
|
|
GBT
75
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $212K | 0.28% |
+28,400
| New | +$715K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.